RT Journal Article
SR Electronic
T1 Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5557
OP 5561
VO 36
IS 10
A1 HIROAKI IWAMOTO
A1 KOUJI IZUMI
A1 YUSUKE SHIMURA
A1 ARIUNBOLD NATSAGDORJ
A1 AERKEN MAOLAKE
A1 YUTA TAKEZAWA
A1 TAKAHIRO NOHARA
A1 KAZUYOSHI SHIGEHARA
A1 YOSHIFUMI KADONO
A1 ATSUSHI MIZOKAMI
YR 2016
UL http://ar.iiarjournals.org/content/36/10/5557.abstract
AB Metastatic urothelial carcinoma is one of the most fatal urological malignancies. Cisplatin-based systemic chemotherapy is the standard treatment for metastatic urothelial carcinoma, and there is little evidence to support metastasectomy. The aims of the study were to evaluate the efficacy of metastasectomy and to investigate the prognoses of the patients. The study included 436 patients with urothelial carcinoma who were treated at our hospital. Of these, we included and retrospectively analyzed 29 patients who received curative treatment for the primary tumor and had been treated for metastases. Seven of these patients underwent metastasectomy. In a multivariate analysis, a serum C-reactive protein level before treatment for metastasis of <1 mg/dl and metastasectomy were independent significant predictors of both better progression-free survival and better overall survival. Metastasectomy may be considered a potential treatment for patients with metastases from urothelial carcinoma.